Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Quadrivalent inactivated split influenza vaccine** is an injectable vaccine containing inactivated and purified antigens from four influenza virus strains: two influenza A subtypes (H1N1, H3N2) and two influenza B lineages (Victoria and Yamagata)[1][2][3][5][6]. The vaccine is produced by growing the viruses in embryonated eggs, inactivating with formaldehyde, and disrupting the viral particles with detergents (e.g. Triton X-100 or sodium deoxycholate), resulting in "split virion" antigens. After injection, the vaccine induces a protective humoral immune response by eliciting the production of antibodies against viral haemagglutinins, which can neutralize circulating influenza viruses and prevent illness. Strains are updated annually according to WHO recommendations to match prevalent circulating viruses[2][3][5][6]. Commonly used for active immunization in children and adults, including pregnant women, and for passive immunization of infants born to vaccinated mothers[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quadrivalent inactivated split influenza vaccine.